In episode nineteen, PeDRA Pub Club host Hannah Chang and guest panelists, Dawn Eichenfield, MD, PhD, and Jinia El-Feghaly, MD discuss the article Survey Access to and Use of Narrowband UVB Phototherapy in Pediatric Vitiligo, published in Pediatric Dermatology in 2025.

PeDRA Annual Conference

Dash for Discovery

In this heartfelt episode of PeDRA Pearls, we shine a spotlight on congenital melanocytic nevi (CMN)—a rare and often misunderstood skin condition present at birth. Tune in to hear Maggie, a physician and mother whose son Reid was born with a giant CMN, and Dr. Harper Price, Division Chief of Pediatric Dermatology at Phoenix Children’s Hospital, as they explore the emotional journey from diagnosis to advocacy, the medical complexities of CMN, and the urgent need for accurate information and coordinated care. You'll also learn about the groundbreaking Nevus Owners Outcomes Registry (NOOR), a collaborative effort between Nevus Outreach and PeDRA that’s paving the way for patient-centered research and improved outcomes for families everywhere.

In this heartwarming episode of PeDRA Pearls, we take a break from our usual research-focused content to spotlight the power of community, creativity, and confidence-building for children with skin conditions. Host Jenn Dawson is joined by Dr. Alanna Bree, founder of Made a Masterpiece, and medical student Alisha Kashyap to discuss their co-authored children’s book Loving the Skin You’re In at Camp Dermadillo. Tune in to learn about the inspiration behind the book, the transformative experience of dermatology camps like Camp Dermadillo and Camp Discovery, and the growing impact of Made a Masterpiece on families across the country.

In our final episode focused on the OX40 pathway and its emerging therapies, Dr. Joy Wan moderates a thoughtful discussion with two leaders from the patient advocacy community. Wendy Smith Begolka, MBS, Chief Program and Mission Officer at the National Eczema Association, and Korey Capozza, MPH, Founder and Executive Director of Global Parents for Eczema Research, share their perspectives on incorporating patient priorities into clinical trials and effectively communicating with patients about new and emerging treatments.

Disclosures:

Joy Wan, MD - Sun Pharmaceuticals – consulting (DMC), Astria Therapeutics – consulting (ad board), Galderma – fellowship funding (paid to Johns Hopkins)

Wendy Smith-Begolka, MBS - Amgen/Kyowa, Kirin, Pfizer, Sanofi  – advisory board honoraria; Arcutis, Incyte, Galderma – speaker fees; Pfizer, Sanofi – research grants

Korey Capozza, MPH - Advisory board honoraria from Amgen, Kyowa Kirin, Incyte, and Pfizer

• 13th PeDRA Annual Conference
• 5th Annual Dash for Discovery
• PeDRA Awards Program
• PeDRA Mentorship Program
• PeDRA Grants
• OX40 Educational Series
• SPD/PeDRA Journal Club

In episode eighteen, PeDRA Pub Club host Hannah Chang and guest panelists, Bella Plumptre, MBBS, and Cheryl Bayart, MD, discuss the article How issues of autonomy and consent differ between children and adults: Kids are not just little people, published in Clinical Dermatology in 2017.

PeDRA and the greater pediatric dermatology community are deeply saddened by the sudden passing of Dr. Robert Sidbury. To donate in his honor, please visit the SPD Foundation.

Welcome to today’s episode of the PeDRA Pearls Podcast! In this installment, Dr. Colleen Cotton is joined by medical student Mana Nasseri to discuss their research project titled "Impact of Bariatric Surgery on Pediatric Hidradenitis Suppurativa." Tune in as they share what inspired this important work, key insights from their findings, and the questions that still remain. Whether you're a clinician, researcher, or simply curious about the intersection of dermatology and pediatric obesity, this episode is full of valuable perspectives you won’t want to miss.

Updates:

• Dash for Discovery
• PeDRA Annual Conference
• PeDRA Awards Program
• PeDRA Mentorship Program - Now Open!

In episode seventeen, PeDRA Pub Club host Hannah Chang and guest panelists, Bella Plumptre, MD, and Cheryl Bayart, MD, discuss a recent PeDRA publication, Dermatologic Conditions in Down Syndrome: A Multi-Site Retrospective Review of International Classification of Diseases published in Pediatric Dermatology in 2024.

PeDRA Awards Program

PeDRA Annual Conference

Following the June 23 OX40 webinar, Dr. Eichenfield, Dr. Simpson, and Dr. Wan continue the conversation with a look ahead at the future of OX40 therapies and their potential to change the course of disease. They also unpack the complex concept of remission in atopic dermatitis—what it means, how it's defined, and whether it's truly achievable.

To watch the OX40 webinar, please click here.

Disclosures:

Lawrence Eichenfield, MD has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Target RWE, T-Rex, and UCB.

Eric Simpson, MD reports personal fees from AbbVie, Aclaris Therapeutics, Amgen, Arcutis, Astria Therapeutics, Attovia Therapeutics, Inc., Bambusa Therapeutics Inc., Castle, CorEvitas, Dermira, Eli Lilly, Evomunne, FIDE, Impetus Healthcare, Incyte, Innovaderm Reche/ Indero, Inmagene Biopharmaceuticals, Janssen, LectureLinx (LLX), Leo, NUMAB Therapeutics AG, Pfizer, Recludix Pharma, Regeneron, Roche Products Ltd, Sanofi-Genzyme, SITRYX Therapeutics

Eric Simpson, MD reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, Dermavant, CorEvitas, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi-Genzyme, Target, VeriSkin

Joy Wan, MD Sun Pharmaceuticals - consulting (DMC), Astria Therapeutics - consulting (ad board), Galderma - fellowship funding (paid to Johns Hopkins)

This engaging and informative webinar explores the role of OX40 and OX40L in pediatric dermatology. OX40: Innovative Insights and Therapeutic Potential in Pediatric Dermatology brings together experts in the field to discuss emerging research, mechanisms of action, and the implications of targeting the OX40 pathway for treating chronic inflammatory skin diseases in children. To view the video version of this webinar, please click here.

Disclosures:

Lawrence Eichenfield, MD has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Target RWE, T-Rex, and UCB.

Eric Simpson, MD reports personal fees from AbbVie, Aclaris Therapeutics, Amgen, Arcutis, Astria Therapeutics, Attovia Therapeutics, Inc., Bambusa Therapeutics Inc., Castle, CorEvitas, Dermira, Eli Lilly, Evomunne, FIDE, Impetus Healthcare, Incyte, Innovaderm Reche/ Indero, Inmagene Biopharmaceuticals, Janssen, LectureLinx (LLX), Leo, NUMAB Therapeutics AG, Pfizer, Recludix Pharma, Regeneron, Roche Products Ltd, Sanofi-Genzyme, SITRYX Therapeutics

Eric Simpson, MD reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, Dermavant, CorEvitas, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi-Genzyme, Target, VeriSkin

Joy Wan, MD Sun Pharmaceuticals - consulting (DMC), Astria Therapeutics - consulting (ad board), Galderma - fellowship funding (paid to Johns Hopkins)